Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-17-009841
Filing Date
2017-05-09
Accepted
2017-05-09 16:07:16
Documents
68
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q akba-10q_20170331.htm 10-Q 1663669
2 EX-4.1 akba-ex41_199.htm EX-4.1 108501
3 EX-10.1 akba-ex101_176.htm EX-10.1 745587
4 EX-31.1 akba-ex311_8.htm EX-31.1 17369
5 EX-31.2 akba-ex312_6.htm EX-31.2 17385
6 EX-32.1 akba-ex321_9.htm EX-32.1 11873
7 EX-99.1 akba-ex991_7.htm EX-99.1 28632
8 GRAPHIC g20170509155152583234.jpg GRAPHIC 12701
9 GRAPHIC g20170509155152238232.jpg GRAPHIC 2066
10 GRAPHIC g20170509155152576233.jpg GRAPHIC 29570
  Complete submission text file 0001564590-17-009841.txt   7963310

Data Files

Seq Description Document Type Size
11 XBRL INSTANCE DOCUMENT akba-20170331.xml EX-101.INS 1656886
12 XBRL TAXONOMY EXTENSION SCHEMA akba-20170331.xsd EX-101.SCH 53239
13 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE akba-20170331_cal.xml EX-101.CAL 55174
14 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE akba-20170331_def.xml EX-101.DEF 186686
15 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20170331_lab.xml EX-101.LAB 382858
16 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20170331_pre.xml EX-101.PRE 300883
Mailing Address 245 FIRST STREET SUITE 1100 CAMBRIDGE MA 02142
Business Address 245 FIRST STREET SUITE 1100 CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 17826427
SIC: 2834 Pharmaceutical Preparations